Correlation analysis of serum CHI3L1, HMGB1 and CD62E detection with the prognosis of Mycoplasma pneumoniae in children

Serum CHI3L1, HMGB1 and CD62E in Mycoplasma pneumoniae in children

  • Hui Yang Department of Clinical Laboratory, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University
  • Tingli Zhang Department of Clinical Laboratory, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University
  • Xiaoqi Zhang Department of Clinical Laboratory, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University
  • Xu Yang Department of Respiratory, Beijing Chaoyang Hospital, Capital Medical University
  • Xiaoan Jiang Department of Respiratory, Beijing Chaoyang Hospital, Capital Medical University
  • Bo Chen Department of Clinical Laboratory, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University
DOI: https://doi.org/10.5937/jomb0-62529
Keywords: High mobility group protein 1, Mycoplasma pneumoniae, Correlation analysis, Chitinase-3-like protein 1, CD62E

Abstract


[Objective] To evaluate the clinical value of serum Chitinase-3-like protein 1 (CHI3L1), high mobility group protein 1 (HMGB1), and CD62E detection for determining the severity and prognosis of Mycoplasma pneumoniae in children.

[Methods] A total of 476 children with Mycoplasma pneumoniae who were diagnosed and treated at this hospital from January 2023 to March 2025 were selected as the Mycoplasma pneumoniae infection group. The healthy control group consisted of 120 kids who had hospital examinations over the same time period. Serum CHI3L1, HMGB1, and CD62E levels were examined between the Mycoplasma pneumoniae infection group and the healthy control group. To investigate the risk factors for a bad outcome in kids infected with Mycoplasma pneumoniae, univariate and multivariate logistic regression analyses were employed. Serum CHI3L1, HMGB1, and CD62E levels were investigated in relation to Mycoplasma pneumoniae severity and their predictive power for a poor outcome.

[Results] HMGB1, CD62E, and CHI3L1 serum levels were significantly greater in the Mycoplasma pneumoniae infection group than in the healthy control group (P<0.05), and they increased as Mycoplasma pneumoniae infection severity increased (P<0.05). The proportion of children with Mycoplasma pneumoniae with pleural effusion, the proportion of children with a treatment course of ≥7 days, the white blood cell count, the duration of antibacterial drug use, and the levels of serum CHI3L1, HMGB1 and CD62E in the poor prognosis group were significantly greater than those in the good prognosis group (P<0.05). However, no statistically significant differences were seen in CRP levels, age, or sex (P>0.05). Elevated serum CHI3L1, HMGB1, and CD62E levels were found to be independent risk factors for the prognosis of Mycoplasma pneumoniae by multivariate analysis (P<0.05). The levels of serum CHI3L1, HMGB1 and CD62E have relatively high efficacy in predicting the poor prognosis of Mycoplasma pneumoniae patients. The sensitivity of the combined detection of the three was 97.9%, the specificity was 90.2%, and the area under the curve was 0.785, which was significantly greater than that of the individual detection of CHI3L1, HMGB1 and CD62E (Z=3.257, 3.429, 4.650, P<0.05).

[Conclusion] The levels of serum CHI3L1, HMGB1 and CD62E are indicators reflecting the severity of Mycoplasma pneumoniae. The combined detection method has high efficacy in predicting the poor prognosis of Mycoplasma pneumoniae patients.

References

1.Wang YS, Zhou YL, Bai GN, Li SX, Xu D, Chen LN, Chen X, Dong XY, Fu HM, Fu Z, Hao CL, Hong JG, Liu EM, Liu HM, Lu XX, Luo ZX, Tang LF, Tian M, Yin Y, Zhang XB, Zhang JH, Zhang HL, Zhao DY, Zhao SY, Zhu GH, Zou YX, Lu Q, Zhang YY, Chen ZM. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae in children. World J Pediatr. 2024 Sep;20(9):901-914. doi: 10.1007/s12519-024-00831-0. Epub 2024 Aug 14. PMID: 39143259; PMCID: PMC11422262.
2.Ding G, Zhang X, Vinturache A, van Rossum AMC, Yin Y, Zhang Y. Challenges in the treatment of pediatric Mycoplasma pneumoniae. Eur J Pediatr. 2024 Jul;183(7):3001-3011. doi: 10.1007/s00431-024-05519-1. Epub 2024 Apr 18. PMID: 38634891.
3.Huang X, Gu H, Wu R, Chen L, Lv T, Jiang X, Li H, Guo B, Liu J, Li D, Zhao D, Liu F. Chest imaging classification in Mycoplasma pneumoniae is associated with its clinical features and outcomes. Respir Med. 2024 Jan;221:107480. doi: 10.1016/j.rmed.2023.107480. Epub 2023 Dec 1. PMID: 38043865.
4.Zhu Y, Luo Y, Li L, Jiang X, Du Y, Wang J, Li H, Gu H, Li D, Tang H, Qin H, Xu C, Liu Y, Zhao D, Guo Y, Liu F. Immune response plays a role in Mycoplasma pneumoniae pneumonia. Front Immunol. 2023 May 26;14:1189647. doi: 10.3389/fimmu.2023.1189647. PMID: 37304280; PMCID: PMC10250694.
5.Xu M, Li Y, Shi Y, Liu H, Tong X, Ma L, Gao J, Du Q, Du H, Liu D, Lu X, Yan Y. Molecular epidemiology of Mycoplasma pneumoniae in children, Wuhan, 2020-2022. BMC Microbiol. 2024 Jan 17;24(1):23. doi: 10.1186/s12866-024-03180-0. PMID: 38229068; PMCID: PMC10792977.
6.Wang C, Wen J, Yan Z, Zhou Y, Gong Z, Luo Y, Li Z, Zheng K, Zhang H, Ding N, Wang C, Zhu C, Wu Y, Lei A. Suppressing neutrophil itaconate production attenuates Mycoplasma pneumoniae. PLoS Pathog. 2024 Nov 5;20(11):e1012614. doi: 10.1371/journal.ppat.1012614. PMID: 39499730; PMCID: PMC11567624.
7.Wang Y, Yu X, Liu F, Tian X, Quan S, Jiao A, Yang X, Zeng X, Jiao W, Qi H, Xu F, Li Q, Liu S, Xu B, Sun L, Shen A. Respiratory microbiota imbalance in children with Mycoplasma pneumoniae. Emerg Microbes Infect. 2023 Dec;12(1):2202272. doi: 10.1080/22221751.2023.2202272. PMID: 37132354; PMCID: PMC10171136.
8.Ding L, Jiang Y. Biomarkers associated with the diagnosis and prognosis of Mycoplasma pneumoniaepneumonia in children: a review. Front Cell Infect Microbiol. 2025 Mar 18;15:1552144. doi: 10.3389/fcimb.2025.1552144. PMID: 40171163; PMCID: PMC11958718.
9.Zhang XB, He W, Gui YH, Lu Q, Yin Y, Zhang JH, Dong XY, Wang YW, Ye YZ, Xu H, Wang JY, Shen B, Gu DP, Wang LB, Wang Y. Current Mycoplasma pneumoniae epidemic among children in Shanghai: unusual pneumonia caused by usual pathogen. World J Pediatr. 2024 Jan;20(1):5-10. doi: 10.1007/s12519-023-00793-9. Epub 2024 Jan 17. PMID: 38231466.
10.Li D, Gu H, Chen L, Wu R, Jiang Y, Huang X, Zhao D, Liu F. Neutrophil-to-lymphocyte ratio as a predictor of poor outcomes of Mycoplasma pneumoniaepneumonia. Front Immunol. 2023 Dec 19;14:1302702. doi: 10.3389/fimmu.2023.1302702. PMID: 38169689; PMCID: PMC10758472.
11.Liu J, He R, Zhang X, Zhao F, Liu L, Wang H, Zhao S. Clinical features and "early" corticosteroid treatment outcome of pediatric mycoplasma pneumoniaepneumonia. Front Cell Infect Microbiol. 2023 Apr 4;13:1135228. doi: 10.3389/fcimb.2023.1135228. PMID: 37082710; PMCID: PMC10110948.
12.Wu L, Li X, Yan J. Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol. 2024 Jul;45:101995. doi: 10.1016/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241.
13.Song X, Zhou N, Lu S, Gu C, Qiao X. New-generation tetracyclines for severe macrolide-resistant Mycoplasma pneumoniae in children: a retrospective analysis. BMC Infect Dis. 2024 Oct 16;24(1):1166. doi: 10.1186/s12879-024-10070-3. PMID: 39407159; PMCID: PMC11481790.
14.Chen Y, Zhang Y, Tang QN, Shi HB. Efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae in children at different periods. Ital J Pediatr. 2024 Mar 5;50(1):38. doi: 10.1186/s13052-024-01615-y. PMID: 38439015; PMCID: PMC10913651.
15.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
16.Yang L, Zhang Y, Shen C, Lu Z, Hou T, Niu F, Wang Y, Ning J, Liu R. Clinical features and risk factors for plastic bronchitis caused by Mycoplasma pneumoniae in children. BMC Pulm Med. 2023 Nov 23;23(1):468. doi: 10.1186/s12890-023-02766-0. Erratum in: BMC Pulm Med. 2023 Dec 11;23(1):499. doi: 10.1186/s12890-023-02800-1. PMID: 37996853; PMCID: PMC10668422.
17.Zhang H, Yang J, Zhao W, Zhou J, He S, Shang Y, Cheng Q. Clinical features and risk factors for plastic bronchitis caused by refractory Mycoplasma pneumoniae in children: a practical nomogram prediction model. Eur J Pediatr. 2023 Mar;182(3):1239-1249. doi: 10.1007/s00431-022-04761-9. Epub 2023 Jan 12. PMID: 36633659; PMCID: PMC10023623.
18.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
19.Jin P, Han C, Guo W, Xu Y. Mycoplasma pneumoniae-associated thromboembolism with plastic bronchitis: a series of five case reports and literature review. Ital J Pediatr. 2024 Jun 18;50(1):117. doi: 10.1186/s13052-024-01690-1. PMID: 38886770; PMCID: PMC11184871.
20.Yu M, Zhang Q, Yan H. Cytokines and refractory Mycoplasma pneumoniae in children: a systematic review. Minerva Pediatr (Torino). 2024 Apr;76(2):259-267. doi: 10.23736/S2724-5276.23.07158-6. Epub 2023 May 8. PMID: 37155205.
21.Wang Z, Peng Y, Yang S, Chen Z, Wang H, Li H, Li X. Risk factors for complications of Mycoplasma pneumoniae in hospitalized children in China: a systematic review and meta-analysis. BMC Pediatr. 2024 Dec 18;24(1):810. doi: 10.1186/s12887-024-05279-9. PMID: 39696115; PMCID: PMC11654151.
22.Lloyd EC, Wolf J. Empiric Antibiotic Therapy for Mycoplasma pneumoniae in Children: A Pro/Con Discussion. J Pediatric Infect Dis Soc. 2025 Sep 11;14(9):piaf075. doi: 10.1093/jpids/piaf075. PMID: 40810495.
23.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
24.Chen L, Yin J, Liu X, Liu J, Xu B, Shen K. Thromboembolic complications of Mycoplasma pneumoniae in children. Clin Respir J. 2023 Mar;17(3):187-196. doi: 10.1111/crj.13584. Epub 2023 Jan 19. PMID: 36658687; PMCID: PMC9978901.
25.Zhuo LY, Hao JW, Song ZJ, Meng H, Wang TD, Yang LL, Yang ZM, Ma JM, Shen D, Cui JJ, Chen WJ, Yang W, Zang LL, Wang JN, Yin XP. Predicting the severity of Mycoplasma pneumoniae in pediatric and adult patients: a multicenter study. Sci Rep. 2024 Oct 3;14(1):22978. doi: 10.1038/s41598-024-74251-5. PMID: 39362944; PMCID: PMC11450145.
26.Sheng Y, Liang Y, Zhao C, Kang D, Liu X. Azithromycin sequential therapy plus inhaled terbutaline for Mycoplasma pneumoniae in children: a systematic review and meta-analysis. BMC Infect Dis. 2024 Jun 28;24(1):653. doi: 10.1186/s12879-024-09564-x. PMID: 38944667; PMCID: PMC11214698.
27.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
28.Zhao X, Lv J, Wu M, Wu Q. Clinical characteristics and risk factors for Mycoplasma pneumoniaepneumonia in children. Front Pediatr. 2024 Dec 23;12:1438631. doi: 10.3389/fped.2024.1438631. PMID: 39764167; PMCID: PMC11701002.
29.Yang S, Liu X, Han Y, Wang H, Mei Y, Wang H, Zhang N, Peng Y, Li X. Clinical characteristics and associated factors of macrolide-resistant Mycoplasma pneumoniae in children: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1505-1522. doi: 10.1007/s10096-025-05101-z. Epub 2025 Mar 19. PMID: 40106136.
30.Yu A, Ran L, Sun X, Feng T. Significance of respiratory virus coinfection in children with Mycoplasma pneumoniae. BMC Pulm Med. 2024 Nov 25;24(1):585. doi: 10.1186/s12890-024-03380-4. PMID: 39587500; PMCID: PMC11590504.
31.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
32.Ss L, Hb L. Severe Mycoplasma pneumoniae combined with cold agglutinin disease and pulmonary embolism in childhood: A case report and review of the literature. Afr J Reprod Health. 2024 Nov 30;28(11):205-215. doi: 10.29063/ajrh2024/v28i11.20. PMID: 39757967.
33.Liu K, Fu HM, Lu Q. [Advancement in epidemiology of Mycoplasma pneumoniae pneumonia in children in China]. Zhonghua Er Ke Za Zhi. 2024 Jul 2;62(7):696-699. Chinese. doi: 10.3760/cma.j.cn112140-20240407-00247. PMID: 38955692.
34.Li S, Zhou J, He J, Yang D, Zhu G, Tang L, Chen Z. Clinical profiles of Mycoplasma pneumoniae in children with different pleural effusion patterns: a retrospective study. BMC Infect Dis. 2024 Sep 4;24(1):919. doi: 10.1186/s12879-024-09829-5. PMID: 39232651; PMCID: PMC11376048.
35.Zhang X, Sun R, Hou J, Jia W, Li P, Song C, Cheng Y. Clinical characteristics and risk factors for pulmonary embolism with Mycoplasma pneumoniae in children. Sci Rep. 2024 Oct 14;14(1):24043. doi: 10.1038/s41598-024-74302-x. PMID: 39402105; PMCID: PMC11479261.
36.Yang L, Zhang C, Liu Y, Bao H, Wang Z. The Therapeutic Potential of Neutrophil Extracellular Traps and NLRP3 Inflammasomes in Mycoplasma pneumoniae Pneumonia. Immunol Invest. 2024 Aug;53(6):975-988. doi: 10.1080/08820139.2024.2364796. Epub 2024 Jun 14. PMID: 38874911.
37.Li P, Wang W, Zhang X, Pan J, Gong L. Observational retrospective clinical study on clinical features of macrolide-resistant Mycoplasma pneumoniae in Chinese pediatric cases. Sci Rep. 2024 Mar 7;14(1):5632. doi: 10.1038/s41598-024-55311-2. PMID: 38453960; PMCID: PMC10920782.
Published
2026/03/16
Issue
Ahead of print
Section
Original paper

Copyright (c) 2026 Hui Yang, Tingli Zhang, Xiaoqi Zhang, Xu Yang , Xiaoan Jiang, Bo Chen

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.